Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 781

Results For "IT"

10347 News Found

ProBioGen’s vaccine production cell line AGE1.CR.pIX used for clinical production
News | January 20, 2023

ProBioGen’s vaccine production cell line AGE1.CR.pIX used for clinical production

The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines


USFDA completes inspection at APL HealthCare
Drug Approval | January 19, 2023

USFDA completes inspection at APL HealthCare

The company has been issued ‘Form 483’ with two observations


Krsnaa Diagnostics operationalized four diagnostics centres for Punjab Govt
Clinical Trials | January 19, 2023

Krsnaa Diagnostics operationalized four diagnostics centres for Punjab Govt

The company has operationalized diagnostics center at Ferozepur, Gurdaspur, Nawanshahr, and Kapurthala in Punjab.


Panacea Biotec donates 125,000 doses of Easyfive-TT to Cuba
News | January 18, 2023

Panacea Biotec donates 125,000 doses of Easyfive-TT to Cuba

This donation will allow the continuation of the cycle of vaccination for children foreseen within the national immunization program carried out by the Ministry of Public Health of Cuba


Cipla launches Cippoint
News | January 18, 2023

Cipla launches Cippoint

Point-of-Care solution to facilitate clinicians in quick and effective decision making


Glenmark to divest select dermatology brands for Rs. 340.48 Cr
News | January 18, 2023

Glenmark to divest select dermatology brands for Rs. 340.48 Cr

The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands


Lonza collaborates Cristal Therapeutics and McSAF to expand Bioconjugates offering
News | January 18, 2023

Lonza collaborates Cristal Therapeutics and McSAF to expand Bioconjugates offering

Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates


1st G20 Health Working Group Meeting to commence on 18th January at Thiruvananthapuram
Policy | January 17, 2023

1st G20 Health Working Group Meeting to commence on 18th January at Thiruvananthapuram

India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health


Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets
Drug Approval | January 17, 2023

Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets

Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)


USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions
Drug Approval | January 17, 2023

USFDA inspections gather pace; Indian pharma companies equipped to handle disruptions

The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22